Please use this identifier to cite or link to this item:
|Title:||Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders|
|Author:||Mallandrich Miret, Mireia|
Calpena Campmany, Ana Cristina
Clares Naveros, Beatriz
Parra Coca, Alexander
García López, María Luisa
Soriano, José L.
Administració de medicaments
Administration of drugs
|Abstract:||Aim: The development and optimization of Ketorolac tromethamine-loaded polylactic-co-glycolic acid nanoparticles (KT-NPs) for the treatment of inflammatory processes of the eye. Materials & methods: KT-NPs were developed by factorial design and characterized by assessing their physicochemical properties. Biopharmaceutical behavior studies, ocular tolerance, anti-inflammatory efficacy and bioavailability tests were performed on pigs. Results: Optimized KT-NPs of 112 nm, narrow distribution with encapsulation efficiency near 100% were obtained. KT release followed the Weibull model and there was significantly greater retention in the cornea and sclera than in the commercial reference. KT-NPs showed no signs of ocular irritancy and similar anti-inflammatory efficacy to the commercial reference. Conclusion: KT-NPs were a suitable alternative for the treatment of inflammatory disorders of the anterior and posterior segments of the eye as an alternative to conventional topical formulations.|
|Note:||Versió postprint del document publicat a: https://doi.org/10.2217/nnm-2020-0403|
|It is part of:||Nanomedicine, 2021, vol. 13, num. 3|
|Appears in Collections:||Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)|
Document embargat fins el 15-2-2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.